Suscribirse

Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia - 17/09/12

Doi : 10.1016/j.gie.2012.04.459 
Hannah P. Kim, BA, William J. Bulsiewicz, MD, MSc, Cary C. Cotton, BA, Evan S. Dellon, MD, MPH, Melissa B. Spacek, FNP, Xiaoxin Chen, MD, PhD, Ryan D. Madanick, MD, Sarina Pasricha, MD, Nicholas J. Shaheen, MD, MPH ⁎
Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA 

Reprint requests: Nicholas Shaheen, MD, MPH, CB#7080, Bioinformatics Building, 130 Mason Farm Rd., UNC-CH, Chapel Hill, NC 27599-7080

Resumen

Background

EMR is commonly performed before radiofrequency ablation (RFA) for nodular dysplastic Barrett's esophagus (BE).

Objective

To determine the efficacy and safety of EMR before RFA for nodular BE with advanced neoplasia (high-grade dysplasia [HGD] or intramucosal carcinoma [IMC]).

Design

Retrospective study.

Setting

University of North Carolina Hospitals, from 2006 to 2011.

Patients

169 patients with BE with advanced neoplasia: 65 patients treated with EMR and RFA for nodular disease and 104 patients treated with RFA alone for nonnodular disease.

Interventions

EMR, RFA.

Main Outcome Measurements

Efficacy (complete eradication of dysplasia, complete eradication of intestinal metaplasia, total treatment sessions, RFA treatment sessions), safety (stricture formation, bleeding, and hospitalization).

Results

EMR followed by RFA achieved complete eradication of dysplasia and complete eradication of intestinal metaplasia in 94.0% and 88.0% of patients, respectively, compared with 82.7% and 77.6% of patients, respectively, in the RFA-only group (P = .06 and P = .13, respectively). The complication rates between the 2 groups were similar (7.7% vs 9.6%, P = .79). Strictures occurred in 4.6% of patients in the EMR-before-RFA group. compared with 7.7% of patients in the RFA-only group (P = .53).

Limitations

Retrospective study at a tertiary-care referral center.

Conclusion

In patients treated with EMR before RFA for nodular BE with HGD or IMC, no differences in efficacy and safety outcomes were observed compared with RFA alone for nonnodular BE with HGD or IMC. EMR followed by RFA is safe and effective for patients with nodular BE and advanced neoplasia.

El texto completo de este artículo está disponible en PDF.

Abbreviations : BE, CED, CEIM, HGD, IMC, ITT, PP, RFA


Esquema


 DISCLOSURE: The following authors received research support for this study: N. J. Shaheen from BARRX Medical and CSA Medical; X. Chen from Takeda Pharmaceuticals North America, Inc. All other authors disclosed no financial relationships relevant to this publication. Research support was provided by a grant from the Doris Duke Charitable Foundation to the University of North Carolina-Chapel Hill (HPK), NIH P30 DK034987 (W.J.B., E.S.D., N.J.S.), and NIH T32 DK007634 (W.J.B.).


© 2012  American Society for Gastrointestinal Endoscopy. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 76 - N° 4

P. 733-739 - octobre 2012 Regresar al número
Artículo precedente Artículo precedente
  • Joseph Barnett Kirsner, MD, PhD
  • Stephen B. Hanauer, David Rubin
| Artículo siguiente Artículo siguiente
  • Comparing apples with apples and oranges: the role of radiofrequency ablation alone versus radiofrequency ablation plus EMR for endoscopic management of Barrett's esophagus with advanced neoplasia
  • David E. Fleischer

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.